JP6684831B2 - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP6684831B2 JP6684831B2 JP2017560573A JP2017560573A JP6684831B2 JP 6684831 B2 JP6684831 B2 JP 6684831B2 JP 2017560573 A JP2017560573 A JP 2017560573A JP 2017560573 A JP2017560573 A JP 2017560573A JP 6684831 B2 JP6684831 B2 JP 6684831B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- compound
- alkyl
- added
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1508747.1A GB201508747D0 (en) | 2015-05-21 | 2015-05-21 | Compounds |
| GB1508747.1 | 2015-05-21 | ||
| PCT/GB2016/051057 WO2016185160A1 (en) | 2015-05-21 | 2016-04-15 | Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515563A JP2018515563A (ja) | 2018-06-14 |
| JP2018515563A5 JP2018515563A5 (https=) | 2019-03-14 |
| JP6684831B2 true JP6684831B2 (ja) | 2020-04-22 |
Family
ID=53506149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560573A Active JP6684831B2 (ja) | 2015-05-21 | 2016-04-15 | 化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10294227B2 (https=) |
| EP (1) | EP3298015B1 (https=) |
| JP (1) | JP6684831B2 (https=) |
| CN (1) | CN107849050B (https=) |
| CA (1) | CA3021550C (https=) |
| ES (1) | ES2780382T3 (https=) |
| GB (1) | GB201508747D0 (https=) |
| WO (1) | WO2016185160A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190366331A1 (en) * | 2016-12-15 | 2019-12-05 | Tunghai University | Assay plate and manufacturing method thereof |
| PL4039675T3 (pl) | 2017-04-18 | 2025-01-07 | Eli Lilly And Company | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe |
| EP3817745A4 (en) * | 2018-07-05 | 2022-04-06 | Icahn School of Medicine at Mount Sinai | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION/DISPUTED COMPOUNDS AND METHODS OF USE |
| EP3753944A1 (en) * | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
| EP4021893A1 (en) | 2019-08-29 | 2022-07-06 | Hibercell, Inc. | Perk inhibiting compounds |
| US20220356186A1 (en) * | 2019-08-29 | 2022-11-10 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| WO2023017264A1 (en) | 2021-08-11 | 2023-02-16 | The University Court Of The University Of Edinburgh | Tyrosine kinase inhibitors |
| JP2024544558A (ja) * | 2021-11-15 | 2024-12-03 | ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド | Src阻害剤としての化合物 |
| WO2023196479A1 (en) | 2022-04-07 | 2023-10-12 | Nuvectis Pharma, Inc. | Tyrosine kinase inhibitors |
| WO2025101874A1 (en) * | 2023-11-08 | 2025-05-15 | Nuvectis Pharma, Inc. | Crystalline salt forms of the tyrosine kinase inhibitor ecf506 |
| WO2025101861A1 (en) * | 2023-11-08 | 2025-05-15 | Nuvectis Pharma, Inc. | Crystalline forms of the tyrosine kinase inhibitor ecf506 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2011094628A1 (en) | 2010-01-28 | 2011-08-04 | University Of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| KR20190043648A (ko) * | 2012-05-31 | 2019-04-26 | 파마사이언스 인크. | 단백질 키나제 저해제 |
| CN105451741A (zh) * | 2013-08-06 | 2016-03-30 | 福建海西新药创制有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
-
2015
- 2015-05-21 GB GBGB1508747.1A patent/GB201508747D0/en not_active Ceased
-
2016
- 2016-04-15 WO PCT/GB2016/051057 patent/WO2016185160A1/en not_active Ceased
- 2016-04-15 CN CN201680042794.5A patent/CN107849050B/zh active Active
- 2016-04-15 CA CA3021550A patent/CA3021550C/en active Active
- 2016-04-15 JP JP2017560573A patent/JP6684831B2/ja active Active
- 2016-04-15 US US15/576,101 patent/US10294227B2/en active Active
- 2016-04-15 ES ES16717993T patent/ES2780382T3/es active Active
- 2016-04-15 EP EP16717993.6A patent/EP3298015B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3021550C (en) | 2023-10-03 |
| CA3021550A1 (en) | 2016-11-24 |
| JP2018515563A (ja) | 2018-06-14 |
| CN107849050B (zh) | 2020-10-13 |
| CN107849050A (zh) | 2018-03-27 |
| EP3298015A1 (en) | 2018-03-28 |
| EP3298015B1 (en) | 2020-01-08 |
| US10294227B2 (en) | 2019-05-21 |
| GB201508747D0 (en) | 2015-07-01 |
| ES2780382T3 (es) | 2020-08-25 |
| US20180127422A1 (en) | 2018-05-10 |
| WO2016185160A1 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6684831B2 (ja) | 化合物 | |
| JP6869947B2 (ja) | 置換キナゾリン化合物ならびにそのg12c変異kras、hrasおよび/またはnrasタンパク質の阻害剤としての使用 | |
| JP6404717B2 (ja) | アミドスピロ環状アミド及びスルホンアミド誘導体 | |
| CN102906090B (zh) | 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用 | |
| WO2020160193A2 (en) | Compounds and uses thereof | |
| WO2018133795A1 (zh) | 一种ezh2抑制剂及其用途 | |
| JP6407955B2 (ja) | クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法 | |
| KR20110022589A (ko) | 혈관 내피 성장 인자 수용체에 대한 특이적 억제제 | |
| CN107531683B (zh) | Usp7抑制剂化合物及使用方法 | |
| JP7850460B2 (ja) | ヘテロ環式カリンringユビキチンリガーゼ化合物及びその使用 | |
| KR20220066074A (ko) | A2a / a2b 억제제로서의 트리아졸로피리미딘 | |
| CA3172987A1 (en) | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer | |
| WO2017148406A1 (zh) | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 | |
| KR20180100373A (ko) | 아스코클로린 유도체 및 ampk 활성제로서의 이의 용도 | |
| TWI723480B (zh) | 用作fgfr4抑制劑的稠環衍生物 | |
| JP2024511466A (ja) | Alk-5阻害剤及びその使用 | |
| WO2015192119A1 (en) | Pyrimidine compounds and methods using the same | |
| WO2020028392A1 (en) | Niclosamide analogues and therapeutic use thereof | |
| CN113677341A (zh) | 双环吡啶组合物及其用于癌症治疗的方法 | |
| WO2025101571A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders | |
| TW201934543A (zh) | 以鋅結合劑為基礎的ebna1專一性化合物 | |
| WO2025045124A1 (zh) | Soat1抑制剂及其应用 | |
| WO2025101588A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| TW202321248A (zh) | 酪胺酸激酶抑制劑 | |
| WO2026025042A1 (en) | P53 targeting compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200310 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200330 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6684831 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |